HTSUS Revision Creates New Section 232 Exemption Pathway for Pharmaceuticals — 2026 Rev. 20
The latest revision to the U.S. Harmonized Tariff Schedule introduces no MFN rate changes, focusing instead on trade remedies. A new Chapter 99 heading establishes a 0% additional duty for certain pharmaceutical products used in clinical trials and R&D, refining the scope of an existing Section 232 program.